HSPB2 and cancer: Consequently, HSPB2 mRNA expression status could be combined with other well-validated clinical biomarkers, which could tailor the therapeutic options aiming to improve the outcome of cancer therapy and a patient’s overall survival, while minimizing the associated risk.